Abivax (ABVX) Competitors $70.91 -1.16 (-1.61%) Closing price 04:00 PM EasternExtended Trading$70.91 0.00 (0.00%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX vs. TEVA, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BBIO, VRNA, and BPMCShould you be buying Abivax stock or one of its competitors? The main competitors of Abivax include Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Abivax vs. Its Competitors Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Teva Pharmaceutical Industries (NYSE:TEVA) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings. Which has more risk and volatility, TEVA or ABVX? Teva Pharmaceutical Industries has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Do institutionals and insiders hold more shares of TEVA or ABVX? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, TEVA or ABVX? Abivax has lower revenue, but higher earnings than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.09-$1.64B-$0.16-98.25AbivaxN/AN/A-$190.71MN/AN/A Does the media refer more to TEVA or ABVX? In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Teva Pharmaceutical Industries and 11 mentions for Abivax. Teva Pharmaceutical Industries' average media sentiment score of 0.96 beat Abivax's score of 0.28 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 10 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TEVA or ABVX more profitable? Abivax has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Abivax's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Abivax N/A N/A N/A Do analysts rate TEVA or ABVX? Teva Pharmaceutical Industries presently has a consensus target price of $24.71, suggesting a potential upside of 57.22%. Abivax has a consensus target price of $92.33, suggesting a potential upside of 30.21%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Abivax 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryTeva Pharmaceutical Industries beats Abivax on 11 of the 14 factors compared between the two stocks. Get Abivax News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricAbivaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.57B$3.07B$5.59B$9.54BDividend YieldN/A2.41%4.73%4.13%P/E RatioN/A6.2119.1622.30Price / SalesN/A314.01445.9598.89Price / CashN/A42.6035.6858.35Price / Book102.777.828.165.60Net Income-$190.71M-$54.52M$3.25B$265.26M7 Day Performance1.59%2.07%0.45%-1.00%1 Month Performance789.71%17.29%8.27%6.09%1 Year Performance541.72%14.95%30.29%23.81% Abivax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXAbivax3.6079 of 5 stars$70.91-1.6%$92.33+30.2%+502.1%$4.57BN/A0.0061Upcoming EarningsTEVATeva Pharmaceutical Industries3.9899 of 5 stars$15.70+2.1%$24.71+57.4%-7.6%$17.64B$16.54B-98.1336,830Positive NewsEarnings ReportInsider TradeGMABGenmab A/S3.5318 of 5 stars$21.98+0.9%$37.80+72.0%-22.2%$13.97B$3.12B12.492,682Upcoming EarningsShort Interest ↑RDYDr. Reddy's Laboratories2.1133 of 5 stars$13.80-1.0%$16.95+22.9%-17.1%$11.64B$334.26B20.9027,811QGENQiagen3.7915 of 5 stars$50.27+0.7%$49.40-1.7%+11.7%$11.10B$1.98B126.045,765News CoverageEarnings ReportAnalyst UpgradeMRNAModerna4.2525 of 5 stars$27.64+0.1%$45.61+65.0%-68.1%$10.68B$3.24B-3.675,800Earnings ReportAnalyst ForecastASNDAscendis Pharma A/S2.6426 of 5 stars$184.15+5.5%$223.67+21.5%+39.2%$10.67B$393.54M-29.321,017Upcoming EarningsVTRSViatris2.2574 of 5 stars$8.94+1.5%$10.40+16.3%-24.7%$10.34B$14.74B-2.8232,000Upcoming EarningsDividend AnnouncementShort Interest ↑BBIOBridgeBio Pharma4.4912 of 5 stars$47.75+0.8%$61.18+28.1%+82.4%$8.99B$221.90M-13.53400News CoverageEarnings ReportVRNAVerona Pharma PLC American Depositary Share2.0076 of 5 stars$105.47+0.3%$109.00+3.3%+401.8%$8.95B$42.28M-52.7430Positive NewsUpcoming EarningsBPMCBlueprint Medicines0.6895 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640Positive News Related Companies and Tools Related Companies TEVA Competitors GMAB Competitors RDY Competitors QGEN Competitors MRNA Competitors ASND Competitors VTRS Competitors BBIO Competitors VRNA Competitors BPMC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVX) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABVX Stock Alerts